Bristol-Myers Squibb (BMY) Upgraded at ValuEngine

Bristol-Myers Squibb (NYSE:BMY) was upgraded by ValuEngine from a “sell” rating to a “hold” rating in a research report issued on Friday.

A number of other equities analysts also recently issued reports on BMY. Societe Generale set a $47.00 price target on Bristol-Myers Squibb and gave the company a “sell” rating in a report on Wednesday, November 14th. BMO Capital Markets upped their price target on Bristol-Myers Squibb from $55.00 to $58.00 and gave the company a “market perform” rating in a report on Friday, November 16th. William Blair reaffirmed an “outperform” rating on shares of Bristol-Myers Squibb in a report on Tuesday, November 27th. Morgan Stanley lowered their price target on Bristol-Myers Squibb from $63.00 to $59.00 and set a “hold” rating for the company in a report on Tuesday, November 6th. Finally, Credit Suisse Group set a $61.00 price target on Bristol-Myers Squibb and gave the company a “hold” rating in a report on Sunday, October 14th. Two equities research analysts have rated the stock with a sell rating, twelve have issued a hold rating and eight have given a buy rating to the stock. The stock presently has an average rating of “Hold” and a consensus price target of $61.95.

Shares of Bristol-Myers Squibb stock traded down $0.17 on Friday, reaching $53.08. 9,402,906 shares of the company were exchanged, compared to its average volume of 7,812,144. Bristol-Myers Squibb has a 1-year low of $46.94 and a 1-year high of $70.05. The company has a market cap of $84.92 billion, a PE ratio of 17.63, a P/E/G ratio of 1.45 and a beta of 1.11. The company has a debt-to-equity ratio of 0.41, a quick ratio of 1.40 and a current ratio of 1.53.

Bristol-Myers Squibb (NYSE:BMY) last announced its quarterly earnings results on Thursday, October 25th. The biopharmaceutical company reported $1.09 earnings per share (EPS) for the quarter, beating the Zacks’ consensus estimate of $0.91 by $0.18. The firm had revenue of $5.69 billion during the quarter, compared to the consensus estimate of $5.72 billion. Bristol-Myers Squibb had a return on equity of 47.89% and a net margin of 6.50%. On average, sell-side analysts predict that Bristol-Myers Squibb will post 3.87 earnings per share for the current fiscal year.

Hedge funds have recently bought and sold shares of the company. Cypress Capital Management LLC WY boosted its holdings in shares of Bristol-Myers Squibb by 154.7% in the third quarter. Cypress Capital Management LLC WY now owns 1,910 shares of the biopharmaceutical company’s stock valued at $119,000 after acquiring an additional 1,160 shares during the period. CSat Investment Advisory L.P. acquired a new stake in shares of Bristol-Myers Squibb in the second quarter valued at approximately $113,000. Landaas & Co. WI ADV acquired a new stake in shares of Bristol-Myers Squibb in the second quarter valued at approximately $131,000. CLS Investments LLC boosted its holdings in shares of Bristol-Myers Squibb by 194.3% in the third quarter. CLS Investments LLC now owns 2,575 shares of the biopharmaceutical company’s stock valued at $160,000 after acquiring an additional 1,700 shares during the period. Finally, Selective Wealth Management acquired a new stake in shares of Bristol-Myers Squibb in the third quarter valued at approximately $184,000. 72.74% of the stock is owned by institutional investors and hedge funds.

Bristol-Myers Squibb Company Profile

Bristol-Myers Squibb Company discovers, develops, licenses, manufactures, markets, and distributes biopharmaceutical products worldwide. The company offers drugs in various therapeutic classes, such as oncology; cardiovascular; immunoscience; and virology, including human immunodeficiency virus (HIV) infection.

Featured Article: Fundamental Analysis – How It Helps Investors

To view ValuEngine’s full report, visit ValuEngine’s official website.

Analyst Recommendations for Bristol-Myers Squibb (NYSE:BMY)

Receive News & Ratings for Bristol-Myers Squibb Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Bristol-Myers Squibb and related companies with MarketBeat.com's FREE daily email newsletter.


Leave a Reply